reports
Notification of managers’ transactions
Ørsted A/S (Orsted) Notification of managers’ transactions 03-May-2024 / 12:57 CET/CEST 3.5.2024 12:57:18 CEST | Ørsted A/S | Managers' Transactions Ørsted A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in Ørsted A/S made by persons discharging managerial responsibilities in Ørsted A/S and/or persons closely associated with them. See the transactions of Chair of Ørsted’s Board of Directors Lene Skole in the attached PDF documents. For further information, please contact: Global Media RelationsCarst...
Shenandoah Telecommunications Company Reports First Quarter 2024 Resul...
Shenandoah Telecommunications Company Reports First Quarter 2024 Results EDINBURG, Va., May 03, 2024 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced first quarter 2024 financial and operating results. Tower segment’s financial results will be presented as discontinued operations in the Company’s Consolidated Financial Statements. Under the new organizational and reporting structure, the Company has one reportable segment in continuing operations. First Quarter 2024 Highlights Glo Fiber Markets added approximate...
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby ...
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world’s most influential individuals in health this yea...
GH Research Reports First Quarter 2024 Financial Results and Provides ...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024Cash, cash equivalents, other financial assets and marketable securities of $214.0 million expected to provide cash runway into 2026 DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasda...
Uniti to Merge with Windstream Creating Premier Insurgent Fiber Provid...
Uniti to Merge with Windstream Creating Premier Insurgent Fiber Provider Scaled Platform and Differentiated Focus on Tier II and III Markets De-levered Balance Sheet and Cash Flow Generation to Support Growth Additional Value Creation Opportunities Include up to $125 Million of Targeted Annual Opex and Capex Synergies and Enhanced Strategic Optionality LITTLE ROCK, Ark., May 03, 2024 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that it has entered into a definitive agreement to merge with Windstream Holdings II, LLC (“Windstream”). Under the terms of th...
Rapid Micro Biosystems Reports First Quarter 2024 Financial Results
Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 79,575 shares, and restricted stock units (RSUs) covering an aggregate of 42,400 shares, of BioCryst common stock. The options and RSUs were granted as of April 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in...
- ABGSC IT Research
- Mikkel Kousgaard Rasmussen
Agios to Present at the RBC Capital Markets Global Healthcare Conferen...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcas...
Perspective Therapeutics to Participate at Upcoming May Investor Confe...
Perspective Therapeutics to Participate at Upcoming May Investor Conferences SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors. Guggenheim Healthcare Talks | Radiopharmaceuticals DayDate: Monday, May 13, 2024Location: Ne...
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and...
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update — Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 — — Multiple presentations of preclinical data demonstrate the potential of the PREDATORTM platform, including in immunology-based diseases — — Company announces cash runway extension through at least th...
Balchem Corporation Reports First Quarter 2024 Financial Results
Balchem Corporation Reports First Quarter 2024 Financial Results MONTVALE, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of $239.7 million, quarterly net earnings of $29.0 million, adjusted EBITDA(a) of $60.9 million, and free cash flow(a) of $26.8 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and...
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastat...
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with high-risk cutaneous squamous cell carcinoma (SCC) tumors located on the head and neck (H&N) will be shared at the 56th American College of Mohs Surgery (ACMS) Annual Meeting, being held May 2-5 in Phoenix. “Mohs surgery is commonly used to remove high-risk SCC tumors located on a patient’s head or neck and is the best method to ensure complete...
ECARX Releases Multiple Intelligent Driving Features for Skyland Pro
ECARX Releases Multiple Intelligent Driving Features for Skyland Pro SHANGHAI, China, May 03, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, today announced the launch of multiple intelligent driving and safety features for its Skyland Pro computing platform, which significantly enhance the intelligent driving experience. The new features were previewed during ECARX’s second Tech Day, which was held in Hangzhou on March 20, 2024, and were released for the first time in the recent version 1.4.0 update for th...
Plug Signs MOU with Allied Green Ammonia for 3GW of Electrolyzer Suppl...
Plug Signs MOU with Allied Green Ammonia for 3GW of Electrolyzer Supply at World-Class Green Ammonia Production Facility LATHAM, N.Y., May 03, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, announced the signing of a memorandum of understanding (MOU) with Allied Green Ammonia (AGA), an Australian Company focused on green ammonia production, to supply up to 3 gigawatts (GW) of Plug electrolyzer capacity for AGA’s upcoming hydrogen to ammonia facility proposed for the Northern Territory of Australi...
Augmedix to Participate in Upcoming Investor Conferences in May and Ju...
Augmedix to Participate in Upcoming Investor Conferences in May and June 2024 SAN FRANCISCO, May 03, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that its management team will participate in the following four investor conferences in May and June 2024. RBC Capital Markets Global Healthcare Conference (New York): Management will participate in a fireside chat on May 15 at 10:30 a.m. ET, and be available for 1x1 investor meetings. The webcast link for the fireside chat can be found at .Benchmark Hea...
Telesat First Quarter 2024 Earnings Conference Call
Telesat First Quarter 2024 Earnings Conference Call OTTAWA, May 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, has scheduled a conference call on Friday, May 10, 2024 at 10:30 a.m. ET to discuss its financial results for the three month period ended March 31, 2024. The call will be hosted by Daniel S. Goldberg, President and Chief Executive Officer, and Andrew Browne, Chief Financial Officer, of Telesat. Prior to the commencement of the call, Telesat will post a news release containing its financial results on i...
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Int...
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine – Trial did not meet primary endpoint – IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preve...
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Develop...
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at...
Galera Adopts Limited Duration Stockholder Rights Agreement
Galera Adopts Limited Duration Stockholder Rights Agreement MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.